15:22 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and cell culture studies suggest inhibiting BARD1, BRCA1, CDK1 or CKD12 could help treat tamoxifen-resistant breast cancer. In tumor tissue from 27 recurrent breast cancer patients whose tumors became resistant...
01:10 , Dec 7, 2016 |  BC Extra  |  Clinical News

GNS identifies disease drivers from CoMMpass data

GNS Healthcare Inc. (Cambridge, Mass.) said it has identified four genes as "top drivers" of high-risk multiple myeloma. Using its machine learning technology, the company is collaborating with the Multiple Myeloma Research Foundation (MMRF) to...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lipopolysaccharide (LPS)

Hematology INDICATION: Transfusion Mouse studies suggest pre-activating a subset of dendritic cells (DCs) could prevent alloimmunity to non- ABO antigens in transfusion patients. In mice transfused with red blood cells (RBCs), depletion of the cDC2...
08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
07:00 , Oct 1, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclin dependent kinase 1 (CDK1; CDC2); CDK2; centrosomal protein 290kDa (CEP290)

Renal disease INDICATION: Renal failure In vitro and mouse studies suggest inhibiting CDK1 and CDK2 could help treat Joubert syndrome cases caused by loss-of-function mutations in CEP290 . Levels of CDK1 and CDK2 were higher...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Mesothelioma Cyclin dependent kinase 1 (CDK1; CDC2) Mouse and in vitro studies identified analogs of the bis(indolyl)imidazole alkaloid nortopsentin that could help treat diffuse malignant...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Clinical News

Dinaciclib: Phase IIb/III started

Ligand began a Phase IIb/III trial to evaluate dinaciclib in patients with refractory CLL. The trial start triggers a $2 million milestone payment from partner Merck under a deal to develop dinaciclib. Ligand said it...
07:00 , Aug 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Cyclin dependent kinase 1 (CDK1; CDC2); CDK2; phosphoinositide 3-kinase (PI3K) Mouse and cell culture studies suggest combined inhibition of CDK1 and CDK2 could...
07:00 , Apr 12, 2012 |  BC Innovations  |  Cover Story

Targeting CDK in triple-negative breast cancer

A team at the University of California, San Francisco has found a dysregulated MYC pathway that underlies the majority of triple-negative breast cancers-a form of the disease with limited treatment options. 1 The researchers also...
07:00 , Aug 4, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Cyclin dependent kinase 5 (CDK5) In vitro studies suggest inhibiting CDK5 could help prevent metastatic cancers. In cellular models of metastasis and in...